Colorado is currently home to 1773 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Contraceptive Hormone and Reward Measurement (CHARM Study)
NCT05058872
Recruiting
Purpose of this study: The purpose of this study is to learn more about how hormonal oral contraceptives affect brain processes and emotional wellbeing. Procedures: If participants agree to participate, the following will happen: 1. Eligibility visit (remote screening session) 2. If participants are eligible to participate in the study, they will be placed in one of two groups. If they are in the first group, they will be asked to take an oral contraception pill ("study drug") every day for 21... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado
Conditions: Oral Hormonal Contraceptive Use, Neural Activity, Mood, Hedonic Function
Register for Updates
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
NCT04944979
Recruiting
The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).
Gender:
ALL
Ages:
Between 2 years and 16 years
Trial Updated:
10/31/2024
Locations: IMMUNOe Health and Research Centers, Centennial, Colorado
Conditions: Primary Immunodeficiency Disease
Register for Updates
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
NCT03981575
Recruiting
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogen... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/31/2024
Locations: University of Colorado - Denver, Denver, Colorado
Conditions: Myotonic Dystrophy 1, DM1
Register for Updates
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708
Recruiting
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
10/30/2024
Locations: University of Colorado, Denver, Aurora, Colorado
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003
Recruiting
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.
Gender:
MALE
Ages:
Between 4 years and 14 years
Trial Updated:
10/30/2024
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Duchenne Muscular Dystrophy
Register for Updates
LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm
NCT04695171
Recruiting
The cohort registry is both retrospective and prospective, multicenter surveillance of subjects who underwent a prior hiatal hernia repair and Magnetic Sphincter Augmentation or fundoplication construction more than 2 years prior to initial study visit.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
10/30/2024
Locations: Institute of Esophageal and Reflux Surgery, Lone Tree, Colorado
Conditions: Hiatal Hernia Large, Gastro Esophageal Reflux, Hiatal Hernia, Hiatal Hernia, Paraesophageal, Reflux, Gastroesophageal, Reflux Acid
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Penrose-Saint Francis Healthcare, Colorado Springs, Colorado
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
AMT-116 in Patients With Advanced Solid Tumors
NCT05725291
Recruiting
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Sarah Cannon Research Institute, Denver, Colorado
Conditions: Advanced Solid Tumor
Register for Updates
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
10/28/2024
Locations: Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Register for Updates
Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
NCT06477172
Recruiting
Non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/25/2024
Locations: Beauty by Buford, Lone Tree, Colorado
Conditions: Post Procedural Erythema
Register for Updates
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
NCT05327127
Recruiting
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: Peak Gastroenterology Associates, Colorado Springs, Colorado
Conditions: NASH
Register for Updates
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954
Recruiting
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Sarah Cannon Research Institute, Denver, Colorado
Conditions: Uveal Melanoma
Register for Updates